Bristol, UK – 5th November 2007, Apitope Technology (Bristol) Ltd., the developer of peptide-based therapies, announces the completion of dosing for all six Multiple Sclerosis (MS) patients in a Phase I/IIa trial of ATX-MS-1467. The therapeutic vaccine was found to be safe and well tolerated in Secondary Progressive Multiple Sclerosis (SPMS) patients.
